scholarly journals Decreased Doublecortin (DCX) immunoreactivity in hippocampus after profound sensorineural hearing loss and vestibular dysfunction in adult mice

2021 ◽  
Vol 17 (4) ◽  
pp. 223-223
Author(s):  
Vincent Van Rompaey ◽  
◽  
Alex Liesenborghs ◽  
Karel Goyvaerts ◽  
Daan De Herd ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Vestibular Dysfunction ◽  
Sensorineural Hearing ◽  
Adult Mice

Evidence of Progressive Delay of Motor Development in Children with Sensorineural Hearing Loss and Concurrent Vestibular Dysfunction

2000 ◽  
Vol 90 (3_suppl) ◽  
pp. 1101-1112 ◽  
Author(s):  
Rose Marie Rine ◽  
Gabrielle Cornwall ◽  
Karen Gan ◽  
Christian LoCascio ◽  
Todd O'Hare ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Motor Development ◽  
Vestibular Dysfunction ◽  
Sensorineural Hearing

scholarly journals Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial

2020 ◽  
Author(s):  
Huawei Li ◽  
Weiming Hao ◽  
Liping Zhao ◽  
Huiqian Yu
Keyword(s):  
Randomized Controlled Trial ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Controlled Trial ◽  
Vestibular Function ◽  
Vestibular Dysfunction ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Hearing Outcome ◽  
Randomized Controlled

Abstract Background Idiopathic sudden sensorineural hearing loss (ISSNHL) is a rapid-onset sensorineural hearing impairment with unclear etiology and unsatisfying treatment effects. Vestibular dysfunction has been considered as a poor indicator in the clinical manifestations and prognosis of ISSNHL, which occurred in approximately 28%-57% cases. Glucocorticoids, administered through oral or intratympanic way, is currently a regular and standard treatment for ISSNHL based on hearing outcome. However, little investigations have been conducted on the recovery process and treatment effects of glucocorticoids on vestibular dysfunctions of ISSNHL. This study aims to compare the efficacy of oral or intratympanic glucocorticoids in ISSNHL with vestibular dysfunction in terms of the pattern and trajectory of possible process of vestibular function recovery.Methods/Design A randomized, outcome-assessor- and analyst-blinded, controlled, clinical trial (RCT) will be carried out. A group of seventy-two patients with ISSNHL complaining of vestibular dysfunction appearing as vertigo, dizziness or imbalance will be recruited and randomized into two arms of either oral or intratympanic glucocorticoids therapy with a 1:1 allocation ratio. The primary outcomes will be vestibular function outcomes assessed by sensory organization test, caloric test, video head impulse test, and vestibular evoked myogenic potentials; the secondary outcomes include self-reported vestibular dysfunction symptoms; dizziness-related handicap, visual analogue scale for vertigo and tinnitus; and pure tone audiometry. Assessment will be performed at baseline and at 1, 2, 4, and 8 weeks post-randomization. To our knowledge, this will be the first randomized controlled trial focusing on the prognosis of vestibular dysfunction in ISSNHL and the efficacy of glucocorticoids therapy for the vestibular dysfunction in this disease.Discussion This trial will be the first RCT study focusing on the progress and prognosis of vestibular dysfunction in ISSNHL. Efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. Trial registration ClinicalTrials.gov, NCT03974867. Registered on July 23, 2019.

Aminoglycoside Ototoxicity in the Neonatal Period: Possible Etiologic Factor in Delayed Postural Control

1981 ◽  
Vol 89 (5) ◽  
pp. 818-821 ◽  
Author(s):  
Lydia Eviatar ◽  
Abraham Eviatar
Keyword(s):  
Hearing Loss ◽  
Postural Control ◽  
Sensorineural Hearing Loss ◽  
Neonatal Period ◽  
Vestibular Dysfunction ◽  
Untreated Group ◽  
Sensorineural Hearing ◽  
Etiologic Factor ◽  
Aminoglycoside Ototoxicity ◽  
Laboratory Evidence

Forty-three infants, treated with aminoglycosides during the neonatal period, were tested repeatedly over a period of two to five years for neurovestibular responses. Results of testing were compared with those obtained from a group of 276 healthy newborns followed simultaneously. No abnormalities were found in the untreated group. Among the treated infants, three had a sensorineural hearing loss and eight had laboratory evidence of vestibular dysfunction and delay of head and postural control.

scholarly journals Novel USH1G homozygous variant underlying USH2-like phenotype of Usher syndrome

2019 ◽  
pp. 112067211987939
Author(s):  
Fabiana D’Esposito ◽  
Viviana Randazzo ◽  
Gilda Cennamo ◽  
Nicola Centore ◽  
Paolo Enrico Maltese ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Retinitis Pigmentosa ◽  
Sensorineural Hearing Loss ◽  
Hearing Impairment ◽  
Usher Syndrome ◽  
Age At Onset ◽  
Vestibular Dysfunction ◽  
Sensorineural Hearing ◽  
Type I ◽  
Missense Variation

Purpose: Usher syndrome (USH) is an autosomal recessive disorder characterized by congenital sensorineural hearing impairment and retinitis pigmentosa. Classification distinguishes three clinical types of which type I (USH1) is the most severe, with vestibular dysfunction as an added feature. To date, 15 genes and 3 loci have been identified with the USH1G gene being an uncommon cause of USH. We describe an atypical USH1G-related phenotype caused by a novel homozygous missense variation in a patient with profound hearing impairment and relatively mild retinitis pigmentosa, but no vestibular dysfunction. Methods: A 26-year-old female patient with profound congenital sensorineural hearing loss, nyctalopia and retinitis pigmentosa was studied. Audiometric, vestibular and ophthalmologic examination was performed. A panel of 13 genes was tested by next-generation sequencing (NGS). Results: While the hearing loss was confirmed to be profound, the vestibular function resulted normal. Although typical retinitis pigmentosa was present, the age at onset was unusually late for USH1 syndrome. A novel homozygous missense variation (c.1187T>A, p.Leu396Gln) in the USH1G gene has been identified as causing the disease in our patient. Conclusions: Genetic and phenotypic heterogeneity are very common in both isolated and syndromic retinal dystrophies and sensorineural hearing loss. Our findings widen the spectrum of USH allelic disorders and strength the concept that variants in genes that are classically known as underlying one specific clinical USH subtype might result in unexpected phenotypes.

scholarly journals Effects of Radiotherapy on Auditory and Vestibular Function

2014 ◽  
Vol 6 (4) ◽  
pp. 1-5
Author(s):  
Sachin Sharad Nilakhe
Keyword(s):  
Hearing Loss ◽  
Radiation Therapy ◽  
Sensorineural Hearing Loss ◽  
Head And Neck ◽  
Conductive Hearing Loss ◽  
Vestibular Dysfunction ◽  
Sensorineural Hearing ◽  
Head And Neck Malignancies ◽  
Number Of Patients ◽  
Conductive Hearing

ABSTRACT Introduction Radiotherapy either primary or adjuvant, is a commonly used modality of treatment in head and neck malignancies. The audiovestibular apparatus is often within the fields of radiation treatment, and hearing loss is a possible complication. This study was undertaken to assess the audiovestibular functions in patients undergoing radiation therapy for head and neck malignancies to determine the type and severity of hearing loss and vestibular dysfunction following radiation therapy. Materials and methods Fifty patients with head and neck malignancies reported to the malignant disease treatment center of INHS Asvini and received radiotherapy as a primary modality of treatment or in combination with surgery during the period May 2003 to Sep 2004 were included in this study. None of these patients had prior treatment by chemotherapy. Conclusion A significant number of patients who were subjected to radiation therapy for head and neck malignancies develop conductive hearing loss is predominant in the immediate postradiation period. Conductive hearing loss is reversible and improves with the conservative line of treatment. Sensorineural hearing loss more commonly affects the higher frequencies and is more common in older patients. Sensorineural hearing loss is more common when radiation doses exceed 60 Gy. There is no conclusive evidence of vestibular dysfunction in patients undergoing radiotherapy for head and neck cancers.

scholarly journals Vestibular Infant Screening (VIS)–Flanders: results after 1.5 years of vestibular screening in hearing-impaired children

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sarie Martens ◽  
Ingeborg Dhooge ◽  
Cleo Dhondt ◽  
Saartje Vanaudenaerde ◽  
Marieke Sucaet ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Participation Rate ◽  
Vestibular Dysfunction ◽  
Hearing Impaired ◽  
Sensorineural Hearing ◽  
Vestibular Evoked Myogenic Potentials ◽  
Infant Screening ◽  
Impaired Children ◽  
Hearing Impaired Children

AbstractDue to the close anatomical relationship between the auditory and vestibular end organs, hearing-impaired children have a higher risk for vestibular dysfunction, which can affect their (motor) development. Unfortunately, vestibular dysfunction often goes unnoticed, as vestibular assessment in these children is not standard of care nowadays. To timely detect vestibular dysfunction, the Vestibular Infant Screening–Flanders (VIS–Flanders) project has implemented a basic vestibular screening test for hearing-impaired infants in Flanders (Belgium) with a participation rate of 86.7% during the first year and a half. The cervical Vestibular Evoked Myogenic Potentials (cVEMP) test was applied as vestibular screening tool to map the occurrence of vestibular (mainly saccular) dysfunction in this population. At the age of 6 months, 184 infants were screened. No refers on vestibular screening were observed in infants with permanent conductive hearing loss. In infants with permanent sensorineural hearing loss, a cVEMP refer rate of 9.5% was observed. Failure was significantly more common in infants with severe-profound compared to those with mild-moderate sensorineural hearing loss (risk ratio = 9.8). Since this is the first regional study with a large sample size and successful participation rate, the VIS–Flanders project aims to set an example for other regions worldwide.

scholarly journals Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Weiming Hao ◽  
Liping Zhao ◽  
Huiqian Yu ◽  
Huawei Li
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Vestibular Function ◽  
Vestibular Dysfunction ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Vestibular Evoked Myogenic Potential ◽  
Hearing Outcome ◽  
Myogenic Potential ◽  
Secondary Outcomes

Abstract Background Idiopathic sudden sensorineural hearing loss (ISSNHL) is a rapid-onset sensorineural hearing impairment with unclear etiology and unsatisfying treatment effects. Vestibular dysfunction has been considered as a poor indicator in the clinical manifestations and prognosis of ISSNHL, which occurred in approximately 28–57% cases. Glucocorticoids, administered through oral or intratympanic way, are currently regularly and standardly applied for ISSNHL to improve the hearing outcome. However, the vestibular prognosis of ISSNHL after routine treatments remains seldom explored. This study aims to compare the effectiveness of oral and intratympanic glucocorticoids in ISSNHL with vestibular dysfunction in terms of the pattern and trajectory of possible process of vestibular function recovery. Methods/design A randomized, outcome-assessor- and analyst-blinded, controlled, clinical trial (RCT) will be carried out. Seventy-two patients with ISSNHL complaining of vestibular dysfunction appearing as vertigo or imbalance will be recruited and randomized into either oral or intratympanic glucocorticoid therapy group with a 1:1 allocation ratio. The primary outcomes will be vestibular function outcomes assessed by sensory organization test, caloric test, video head impulse test, cervical vestibular evoked myogenic potential, and ocular vestibular evoked myogenic potential; the secondary outcomes include self-reported vestibular dysfunction symptoms; dizziness-related handicap, visual analogue scale for vertigo and tinnitus; and pure tone audiometry. Assessments of primary outcomes will be performed at baseline and at 4 and 8 weeks post-randomization, while assessments of secondary outcomes will be performed at baseline and 1, 2, 4, and 8 weeks post-randomization. Discussion Previous intervention studies of ISSNHL included only hearing outcomes, with little attention paid on the prognosis of vestibular dysfunction. This trial will be the first RCT study focusing on the progress and prognosis of vestibular dysfunction in ISSNHL. The efficacy of two commonly used therapies of glucocorticoids will be compared in both auditory and vestibular function fields, rather than in the hearing outcome alone. Trial registration ClinicalTrials.gov NCT03974867. Registered on 23 July 2019

Sign in / Sign up

Export Citation Format

Share Document